Cullinan Therapeutics Narrows Loss, Advances FLT3 Program to Phase 2
Cullinan Therapeutics reported a net loss of $53.7 million in the second quarter, a 23% improvement from a year earlier, as it moved its lead FLT3 program toward a registrational Phase 2 study.
Cullinan Therapeutics (CGEM), a clinical-stage biopharmaceutical company developing therapies in oncology and autoimmune disease, narrowed its second-quarter net loss to $53.7 million from $70.1 million a year earlier, a 23% improvement driven by lower research and development spending.
The quarter's most consequential development came from CLN-049, the company's FLT3 T-cell engager. As recently as the first-quarter release, Cullinan had described the program in terms of a planned dose-escalation update and recommended Phase 2 dose determination expected in the second half of 2026. The anchor release instead disclosed a positive End-of-Phase 1 meeting with the FDA in July and a newly announced Phase 2 study, described as potentially registrational, set to begin in the third quarter of 2026. That shift moves CLN-049 from an exploratory dose-finding effort onto a registrational track months ahead of the timeline Cullinan had set out at the start of the year.
Operating expenses fell to $57.3 million from $75.8 million, with research and development spending down 27% to $44.4 million from $61.0 million and general and administrative costs down 14% to $12.8 million from $14.8 million. The expense reductions accounted for most of the improvement in net loss, since interest income also declined to $3.6 million from $5.9 million as Cullinan's investment balance shrank.
Cash, investments and interest receivable stood at $356.0 million as of June 30, 2026, down from $438.96 million at the end of 2025 and from $393.3 million at the end of the first quarter, a sequential decline of roughly $37 million. Despite that drawdown, Cullinan reiterated guidance that its cash runway extends into 2029, unchanged from the first-quarter release.
Beyond CLN-049, Cullinan's autoimmune pipeline showed a similar pattern of firming timelines. Data from a multi-dose regimen of CLN-978 in rheumatoid arthritis remains guided for the third quarter of 2026, a timeline the company has now repeated across three consecutive releases, while multi-dose data in systemic lupus erythematosus is guided to the fourth quarter.
The anchor release also disclosed, for the first time with this level of specificity, that Phase 2 expansion studies for CLN-978 in both lupus and rheumatoid arthritis, alongside a Phase 2 expansion for velinotamig, are now planned to begin in early 2027. The velinotamig program itself was described in broader terms than before: the first-quarter release referenced only a China-based Phase 1 study in lupus with expansion into unspecified additional indications, while the anchor release named that expansion as a global Phase 1/2 basket study in autoimmune cytopenias, covering immune thrombocytopenia and autoimmune hemolytic anemia, also starting in early 2027.
Taken together, the quarter showed Cullinan trimming costs while accelerating the clinical timeline for its lead oncology asset and expanding the scope of its autoimmune franchise, even as its cash position continued to decline toward a runway the company maintains will last into 2029.